BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11716232)

  • 1. Interaction of bisphosphonates with calcitonin in monitoring medullary carcinoma of the thyroid.
    Osborne ME; Brown RS; Hoskin PJ
    Clin Oncol (R Coll Radiol); 2001; 13(5):370-1. PubMed ID: 11716232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent hypercalcitoninemia in patients with medullary thyroid cancer.
    Misso C; Calzolari F; Puxeddu E; Lucchini R; Monacelli M; Giammartino C; Sanguinetti A; d'Ajello M; Ragusa M; Avenia N
    Tumori; 2009; 95(4):484-7. PubMed ID: 19856661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. True mixed medullary papillary carcinoma of the thyroid: a case report with low blood calcitonin levels.
    Zoroquiain P; Torres J; Goñi I; Fernández L; Solar A
    Endocr Pathol; 2012 Sep; 23(3):168-71. PubMed ID: 22733476
    [No Abstract]   [Full Text] [Related]  

  • 4. Calcitonin-like polypeptides without apparent biological activity in a patient with recurrent medullary thyroid carcinoma.
    Nakajima K; Jinkawa I; Hirota T; Ikeda T; Tugawa M; Minami Y; Hanada M
    Intern Med; 1995 Sep; 34(9):896-900. PubMed ID: 8580565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medullary thyroid carcinoma.
    Evans DB; Burgess MA; Goepfert H; Gagel RF
    Curr Ther Endocrinol Metab; 1997; 6():127-32. PubMed ID: 9174720
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical significance and cost-benefit analysis of serum calcitonin assay in diagnosis and treatment of medullary thyroid carcinoma].
    Hao WJ; Zhang H; Yu Y; Zhao J; Ge ZJ; Ding PX; Sun XX; Liu H; Wen SY; You J
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jul; 54(7):506-509. PubMed ID: 31315357
    [No Abstract]   [Full Text] [Related]  

  • 7. Medullary thyroid carcinoma: genetic advances, treatment recommendations, and the approach to the patient with persistent hypercalcitoninemia.
    Chi DD; Moley JF
    Surg Oncol Clin N Am; 1998 Oct; 7(4):681-706. PubMed ID: 9735129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma.
    Diez JJ; Iglesias P
    Thyroid; 2004 Nov; 14(11):984-5. PubMed ID: 15678599
    [No Abstract]   [Full Text] [Related]  

  • 9. "Hook effect" in calcitonin immunoradiometric assay in patients with metastatic medullary thyroid carcinoma: case report and review of the literature.
    Leboeuf R; Langlois MF; Martin M; Ahnadi CE; Fink GD
    J Clin Endocrinol Metab; 2006 Feb; 91(2):361-4. PubMed ID: 16278263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medullary thyroid cancer.
    Moley JF
    Surg Clin North Am; 1995 Jun; 75(3):405-20. PubMed ID: 7747249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Increased blood CEA level as initial manifestation of medullary thyroid carcinoma].
    Behr TM; Becker W
    Dtsch Med Wochenschr; 1999 Mar; 124(10):303-4. PubMed ID: 10191829
    [No Abstract]   [Full Text] [Related]  

  • 12. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases.
    Hahm JR; Lee MS; Min YK; Lee MK; Kim KW; Nam SJ; Yang JH; Chung JH
    Thyroid; 2001 Jan; 11(1):73-80. PubMed ID: 11272100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer.
    Machens A; Hoffmann F; Sekulla C; Dralle H
    Endocr Relat Cancer; 2009 Dec; 16(4):1291-8. PubMed ID: 19726541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medullary thyroid carcinoma in a patient with Hashimoto's thyroiditis diagnosed by calcitonin washout from a thyroid nodule.
    Mousa U; Gursoy A; Ozdemir H; Moray G
    Diagn Cytopathol; 2013 Jul; 41(7):644-6. PubMed ID: 22102446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Markedly elevated serum calcitonin concentrations associated with initial presentation but not the recurrent presentation of medullary thyroid carcinoma.
    Bodenner D; Nalley C; Chien C; Clarke B; Spring PM; Stack BC
    Thyroid; 2010 Aug; 20(8):927-9. PubMed ID: 20677998
    [No Abstract]   [Full Text] [Related]  

  • 16. Medullary thyroid cancer with undetectable serum calcitonin.
    Brutsaert EF; Gersten AJ; Tassler AB; Surks MI
    J Clin Endocrinol Metab; 2015 Feb; 100(2):337-41. PubMed ID: 25490273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-cell hyperplasia and medullary thyroid carcinoma in patients routinely screened for serum calcitonin.
    Kaserer K; Scheuba C; Neuhold N; Weinhäusel A; Vierhapper H; Haas OA; Niederle B
    Am J Surg Pathol; 1998 Jun; 22(6):722-8. PubMed ID: 9630179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels.
    Machens A; Lorenz K; Dralle H
    Ann Surg; 2009 Aug; 250(2):305-10. PubMed ID: 19638924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules.
    Rieu M; Lame MC; Richard A; Lissak B; Sambort B; Vuong-Ngoc P; Berrod JL; Fombeur JP
    Clin Endocrinol (Oxf); 1995 May; 42(5):453-60. PubMed ID: 7621562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should serum calcitonin be measured routinely in all patients with nodular thyroid disease?
    Sheppard MC
    Clin Endocrinol (Oxf); 1995 May; 42(5):451-2. PubMed ID: 7621561
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.